Compare LQDA & WDFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | WDFC |
|---|---|---|
| Founded | 2004 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2020 | 1995 |
| Metric | LQDA | WDFC |
|---|---|---|
| Price | $37.80 | $214.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $41.00 | ★ $270.00 |
| AVG Volume (30 Days) | ★ 1.1M | 170.5K |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | ★ 1.91% |
| EPS Growth | ★ 51.81 | 30.92 |
| EPS | N/A | ★ 2.78 |
| Revenue | $158,320,000.00 | ★ $488,109,000.00 |
| Revenue This Year | $278.87 | $7.14 |
| Revenue Next Year | $57.13 | $6.02 |
| P/E Ratio | ★ N/A | $76.66 |
| Revenue Growth | ★ 1031.18 | 19.49 |
| 52 Week Low | $11.85 | $175.38 |
| 52 Week High | $46.67 | $253.24 |
| Indicator | LQDA | WDFC |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 51.52 |
| Support Level | $31.75 | $215.00 |
| Resistance Level | $39.19 | $225.39 |
| Average True Range (ATR) | 2.12 | 7.43 |
| MACD | 0.09 | 1.00 |
| Stochastic Oscillator | 37.52 | 66.18 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.